January 2, 2023 — IBA, a world chief in particle accelerator know-how, right this moment confirmed that it has signed a contract with the Spanish Ministry of Well being to put in ten proton remedy methods throughout Spain as a part of a big public tender. This follows the announcement in August that IBA had certified as the one provider of the tender.
The entire worth of the contract to IBA is at present EUR 217 million, all taxes excluded, for the ten methods to be put in at 9 totally different websites in Spain. The contract doesn’t embrace the standard multi-year upkeep element which will probably be negotiated at a later stage. Income recognition will begin in 2022.
The undertaking is being funded by the Amancio Ortega Basis, which signed an settlement with the Spanish Ministry of Well being in 2021 beneath which the Basis agreed to donate funds for the acquisition of 10 proton remedy methods to be put in throughout Spain.
Olivier Legrain, Chief Government Officer of IBA commented: “This important contract win for IBA is a testomony to the world-class high quality of our providing and validates our established standing because the proton remedy market chief with the distinctive capability to answer a contract of such scale. We sit up for working intently with the 9 facilities throughout Spain to ship this life-saving remedy to their sufferers.”
Luk Herremans, Government Vice President of IBA Proton Remedy added: “Securing such a significant public tender underlines the rising significance of proton remedy within the remedy of most cancers, in a market that continues to see sturdy momentum globally with extra medical proof being generated on the remedy modality than ever earlier than. We welcome these new Spanish facilities to our IBA Campus group, which is the most important on the earth and the place they’ll have the ability to each study from and share with different members with a view to present cutting-edge most cancers care to their sufferers.
For extra data: www.iba-worldwide.com
Associated Radioisotope Content material:
NorthStar Medical Radioisotopes Pronounces Provide Settlement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Provide Settlement for Therapeutic Radioisotope Actinium-225 (Ac-225)
Replace on HFR Reactor Outage – Medical Isotope Provide Returning to Regular
Replace on Unplanned Outage of the HFR Reactor
SNMMI Points Alert That HFR Outage Will Influence Isotope Provide
NorthStar Medical Radioisotopes Advances Concentrate on Therapeutic and Specialised SPECT Radiopharmaceuticals
How Nuclear Fusion is Revolutionizing Medical Isotope Manufacturing
FDA Approves Extra Molybdenum-99 (Mo-99) Filling Strains at NorthStar Medical Radioisotopes
Medical Isotope Business Opposes Export of Extremely Enriched Uranium for IRE
IBA and NorthStar Medical Radioisotopes Increase Collaboration to Allow World Availability of Tc-99m
